Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
| Autor: | Markus Kapp, Christina Bluemel, Ingo Hartlapp, Ulrich Steger, Volker Kunzmann, Ken Herrmann |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty FOLFIRINOX medicine.medical_treatment 5-Fluorouracil Nab-paclitaxel Irinotecan lcsh:RC254-282 Neoadjuvant chemotherapy Locally advanced disease Internal medicine Pancreatic cancer Medicine Neoadjuvant therapy ddc:616 Published online: September 2014 business.industry Folinic acid medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Chemotherapy regimen Gemcitabine Oxaliplatin business Chemoradiotherapy medicine.drug |
| Zdroj: | Case Reports in Oncology Case Reports in Oncology, Vol 7, Iss 3, Pp 648-655 (2014) |
| ISSN: | 1662-6575 |
| Popis: | The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy regimen consisting of 2 cycles of nab-paclitaxel plus gemcitabine followed by 4 cycles of FOLFIRINOX. Neoadjuvant chemotherapy resulted in secondary resectability (R0 resection). After 2 cycles of nab-paclitaxel plus gemcitabine, the patient already had a complete metabolic remission as measured by integrated fludeoxyglucose (18F) positron emission tomography and computerized tomography. After a follow-up of 18 months the patient is alive without progression of disease. We propose to assess the clinical benefit of sequencing the combinations nab-paclitaxel plus gemcitabine and FOLFIRINOX as neoadjuvant therapy for patients with locally advanced and initially unresectable pancreatic cancer in a controlled clinical trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|